Abstract Body

TDF-containing PrEP has been associated with decreases in bone mineral density (BMD) in both men and women. The BMD effects of non-TDF-containing PrEP regimens have not been reported.

The HPTN 069/ACTG 5305 study randomized U.S. men and women at risk for HIV-infection to one of 4 double-blinded, placebo-controlled regimens: maraviroc (MVC), MVC+emtricitabine (FTC), MVC+TDF, or TDF+FTC to test the safety and tolerability of these regimens. BMD was measured at the lumbar spine (LS) and hip by dual-energy x-ray absorptiometry (DXA) at baseline and 48 weeks. Adherence was assessed by detectable plasma drug concentrations (TFV and FTC: 0.31 ng/mL; MVC: 0.5 ng/mL) at 24 and 48 weeks. Percentage change in LS and hip BMD was compared between the TDF- and non-TDF (MVC±FTC) containing arms by multivariate linear regression adjusting for sex, race and baseline BMI.

At baseline (n=397), the median age was 32 years, 53% male, 46% black, and median Z-scores were -0.6 and -0.4 at the LS and hip respectively. Overall at the LS, the percentage change in BMD was +0.19% in the TDF arms and +0.66 % in the non-TDF arms (between group difference, -0.48% (95% CI, -1.22, 0.26)). Overall at the hip, the percentage change in BMD was -0.85% in the TDF arms and 0.09% in the non-TDF arms (between group difference, -0.94 (95% CI, -1.74, -0.13)). Among those who had detectable drugs concentrations at 24 and 48 weeks, at the LS (n=129), the percentage change in BMD was +0.89% in the TDF arms and +1.11% in the non-TDF arms (between group difference, -0.22% (95% CI, -1.36, 0.92), p=0.70). At the hip (n=131), the percentage change in BMD was -2.89% in the TDF arms and -0.95 % in the non-TDF arms (between group difference, -1.94% (95% CI, -3.23, -0.65), p=0.003). The between-group differences in percentage change in BMD did not differ by sex at either the LS or hip.

TDF-containing PrEP was associated with greater bone loss compared to non-TDF MVC±FTC PrEP at the hip, but not the lumbar spine in both men and women.